Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tri Zinidol
- Development stage
- Unknown
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tri Zinidol is a fixed-dose combination medication developed by Zinnia Life Sciences, designed to manage pain and inflammation while minimizing gastrointestinal side effects. It is available in two primary formulations: a tablet containing aceclofenac, paracetamol, and rabeprazole sodium, and a capsule containing sustained-release aceclofenac and enteric-coated rabeprazole sodium. Aceclofenac and paracetamol function as analgesics and anti-inflammatory agents by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, which reduces the synthesis of pain-inducing prostaglandins. Rabeprazole sodium, a proton pump inhibitor, suppresses gastric acid secretion by covalently inhibiting the gastric H+/K+-ATPase pump, thereby protecting the stomach lining from NSAID-induced irritation and ulceration. Tri Zinidol is approved for the treatment of pain and inflammation associated with musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
- Brand names
- Tri ZinidolTri Zinidol+
- Other names
- aceclofenac + paracetamol + rabeprazoleaceclofenac + paracetamol + rabeprazole sodiumaceclofenac + rabeprazoleaceclofenac + rabeprazole sodium
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)ATP4B (Potassium-transporting ATPase subunit beta)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Tri Zinidol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tri Zinidol.